Quintessence Biosciences, Inc. is a biopharmaceutical company focused on development of novel protein-based therapeutics as anti-cancer agents. The Company’s products are based on the EVade™ Ribonuclease Technology which allows for the engineering of human proteins (ribonucleases) for the treatment of human diseases. The EVade™ Ribonuclease technology is covered by patents acquired by the Company through an exclusive license with the University of Wisconsin. The Company has advanced lead candidate QBI-139 into a Phase I human clinical trial at the University of Wisconsin Comprehensive Cancer Center.Second generation products are under development and pre-clinical work is ongoing.

Research Grants show all

NIH7

Publications show all

Quintessence Biosciences has published 4 articles.

Patents show all

16Issued15Applications

Clinical Trials show all

1Phase 1

SEC Filings show all

D2

SEC Form D Funding Events

DateOfferedSoldType
2012-06-26$1,486,000$1,486,000Equity
2008-02-29UnknownUnknownOther (Paper Filing)

Key Executives

  • Ronald T. Raines
    Director
  • Laura L. Kiessling
    Director
  • Ralph Kauten
    Executive Officer, Director
  • Laura E. Strong
    Executive Officer